Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has released the "Implementation Rules for the Exit Mechanism of Clinical Translation and Application of New Biomedical Technologies" (the "Rules"), aiming…

Novo Nordisk's Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
CompanyDrug

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Allergan Aesthetics' JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips
CompanyDrug

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

CompanyDrug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Peijia Medical Wins NMPA Approval for GeminiOne TEER System – A Novel Transcatheter Edge‑to‑Edge Repair Device for Mitral Regurgitation in China
CompanyMedical Device

Peijia Medical Wins NMPA Approval for GeminiOne TEER System – A Novel Transcatheter Edge‑to‑Edge Repair Device for Mitral Regurgitation in China

CompanyDrug

Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape

Novo Nordisk's Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China's Broadest‑Label Long‑Acting Growth Hormone
CompanyDrug

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen
CompanyDrug

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market
CompanyDrug

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

AstraZeneca's Etcamah (Camizestrant) Misses SERENA‑4 Primary PFS Endpoint in First‑Line Advanced Breast Cancer – Next‑Generation Oral SERD Falls Short Against Anastrozole Plus Palbociclib
CompanyDrug

AstraZeneca’s Etcamah (Camizestrant) Misses SERENA‑4 Primary PFS Endpoint in First‑Line Advanced Breast Cancer – Next‑Generation Oral SERD Falls Short Against Anastrozole Plus Palbociclib

GSK's ROS1 Inhibitor Jideytro (Zidesamtinib) Posts 94 % Response Rate in TKI‑Naïve ROS1‑Positive NSCLC – Phase I/II ARROS‑1 Delivers Durable Responses With 90 % 12‑Month PFS
CompanyDrug

GSK’s ROS1 Inhibitor Jideytro (Zidesamtinib) Posts 94 % Response Rate in TKI‑Naïve ROS1‑Positive NSCLC – Phase I/II ARROS‑1 Delivers Durable Responses With 90 % 12‑Month PFS

Bayer’s Sevabertinib Granted FDA Accelerated Approval – First‑Line Oral TKI for HER2‑Mutant Non‑Small Cell Lung Cancer

Bayer's Sevabertinib Granted FDA Accelerated Approval – First‑Line Oral TKI for HER2‑Mutant Non‑Small Cell Lung Cancer

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib as a first‑line treatment option for adult patients with locally advanced or metastatic non‑squamous non‑small cell lung cancer (NSCLC) whose tumors…

Eli Lilly Completes Acquisition of AtaiBeckley for up to USD 3.8 Billion – Deal Secures BPL‑003 Rapid‑Acting Neuroplastogen for Treatment‑Resistant Depression

Eli Lilly Completes Acquisition of AtaiBeckley for up to USD 3.8 Billion – Deal Secures BPL‑003 Rapid‑Acting Neuroplastogen for Treatment‑Resistant Depression

Merck's KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China's Only Approved PD‑1 Perioperative Breast Cancer Therapy
CompanyDrug

Merck’s KEYTRUDA (Pembrolizumab) Wins NMPA Approval in Early‑Stage High‑Risk TNBC – Label Expansion Beyond PD‑L1 CPS ≥ 20 for China’s Only Approved PD‑1 Perioperative Breast Cancer Therapy

Diagens Biotechnology and AntAngelMed Forge Three‑Year Pact on Medical Imaging AI – iMedImage Platform Anchors Zhejiang's Provincial "Digital and Intelligent Imaging" Build‑Out
CompanyDeals

Diagens Biotechnology and AntAngelMed Forge Three‑Year Pact on Medical Imaging AI – iMedImage Platform Anchors Zhejiang’s Provincial “Digital and Intelligent Imaging” Build‑Out

MediLink's Roche‑Partnered B7‑H3 ADC Tambotatug Pelitecan Cuts Death Risk 54 % vs. Topotecan in Relapsed Small‑Cell Lung Cancer – Phase III TAISHAN‑302 Meets Primary OS Endpoint
CompanyDrug

MediLink’s Roche‑Partnered B7‑H3 ADC Tambotatug Pelitecan Cuts Death Risk 54 % vs. Topotecan in Relapsed Small‑Cell Lung Cancer – Phase III TAISHAN‑302 Meets Primary OS Endpoint

Hengrui's HER3 ADC Ruzaltatug Rezetecan Wins China Breakthrough Therapy Designation – A New Option for EGFR‑Mutant NSCLC After TKI Failure
CompanyDrug

Hengrui’s HER3 ADC Ruzaltatug Rezetecan Wins China Breakthrough Therapy Designation – A New Option for EGFR‑Mutant NSCLC After TKI Failure

CompanyDrug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products
CompanyDeals

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China‑based Clinical Research Organization (CRO), and Zhejiang Maiyata Microbial Inspection Intelligent Technology Co., Ltd. held a strategic cooperation signing ceremony at…

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
CompanyDeals

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

CompanyDeals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

CompanyDeals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
CompanyDeals

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

- Advertisement -
CompanyDeals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
CompanyDeals

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

CompanyDeals

NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline

Simnova Closes ~RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
CompanyDeals

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China
Policy / Regulatory

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China

China's National Medical Products Administration (NMPA) issued the Announcement on Further Optimizing the Requirements for Application Materials of Process Validation for Innovative Chemical Drugs (Draft for Comments), seeking public feedback…

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

More News

CompanyDrug

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

GSK's Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility
CompanyDrug

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Hengrui's Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications
CompanyDrug

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Roche's Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD
CompanyDrug

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

CompanyDrug

AbbVie’s Atogepant Meets All Endpoints in Phase III LUNA Study – Oral CGRP Antagonist Shows Superior Efficacy in Menstrual Migraine Prevention

CompanyDrug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

Merck Launches Clesrovimab in China – World's First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
CompanyDrug

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

CompanyDrug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Show More